

November 25, 2019
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
 Issued by way of Third Party Allotment**

TOKYO, Japan, November 25, 2019—Symbio Pharmaceuticals Limited announces the large volume exercise of the 47th Stock Acquisition Rights, issued and allotted to EVO FUND on April 25, 2018, during the period from November 14, 2019 to November 25, 2019, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 47 th Stock Acquisition Rights
(2)	Number of issued shares from the exercise start date (November 14, 2019)	400,000 Shares
(3)	Number of stock acquisition rights being exercised from the exercise start date and the ratio to the entire issue	1,600,000 Units (Ratio to the total number of stock acquisition rights issued 15,000,000 units : 10.67%)
(4)	Number of unexercised stock acquisition rights as of the exercise start date	15,000,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	13,400,000 Units

(6) Exercise status from the exercise start date

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
November 14(Thu) ~November 20(Wed)	—	—	665	—
November 21(Thu)	—	—	609	—
November 22(Fri)	200,000	—	609	800,000
November 25(Mon)	200,000	—	609	800,000

※Number of issued shares at the end of the previous month : 24,362,681 shares [of which 11,068 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.